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Abstract
Background: Biological processes are controlled by transcription networks. Expression changes of transcription
factor (TF) genes in precancerous lesions are therefore crucial events in tumorigenesis. Our aim was to obtain a
comprehensive picture of these changes in colorectal adenomas.
Methods: Using a 3-pronged selection procedure, we analyzed transcriptomic data on 34 human tissue samples
(17 adenomas and paired samples of normal mucosa, all collected with ethics committee approval and written,
informed patient consent) to identify TFs with highly significant tumor-associated gene expression changes whose
potential roles in colorectal tumorigenesis have been under-researched. Microarray data were subjected to stringent
statistical analysis of TF expression in tumor vs. normal tissues, MetaCore-mediated identification of TF networks
displaying enrichment for genes that were differentially expressed in tumors, and a novel quantitative analysis of
the publications examining the TF genes’ roles in colorectal tumorigenesis.
Results: The 261 TF genes identified with this procedure included DACH1, which plays essential roles in the proper
proliferation and differentiation of retinal and leg precursor cell populations in Drosophila melanogaster. Its possible
roles in colorectal tumorigenesis are completely unknown, but it was found to be markedly overexpressed (mRNA
and protein) in all colorectal adenomas and in most colorectal carcinomas. However, DACH1 expression was absent
in some carcinomas, most of which were DNA mismatch-repair deficient. When networks were built using the set
of TF genes identified by all three selection procedures, as well as the entire set of transcriptomic changes in
adenomas, five hub genes (TGFB1, BIRC5, MYB, NR3C1, and TERT) where identified as putatively crucial components
of the adenomatous transformation process.
Conclusion: The transcription-regulating network of colorectal adenomas (compared with that of normal colorectal
mucosa) is characterized by significantly altered expression of over 250 TF genes, many of which have never been
investigated in relation to colorectal tumorigenesis.
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Background
Colorectal adenomas are benign tumors of the large in-
testinal epithelium. They are found in roughly one third
of asymptomatic adults who undergo colonoscopy be-
fore the age of 50. Endoscopic removal of these lesions
is associated with high rates of recurrence (up to 60% at
three years, depending on the size, number, histological
features, and degree of dysplasia [1]). In addition, it has
been estimated that 15% of adenomas measuring 1 cm
or more become carcinomas within 10 years of their
detection [2].
Adenomatous transformation of normal colorectal mu-
cosa is associated with profound changes in the tissue’s
gene expression profile [3]. These changes are caused by
epigenetic and/or genetic events that “reprogram” the regu-
lation of gene transcription [4]. An early—and probably
fundamental—event in this reprogramming process in-
volves qualitative, quantitative, and spatial subversion of the
Wnt signaling pathway, the physiological regulator of epi-
thelial homeostasis [5]. Almost invariably, it stems from
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mutations in genes encoding Wnt pathway components
(APC, adenomatous polyposis coli, in most cases), which
lead to the accumulation of β-catenin in both the cytoplasm
and nucleus. In the latter compartment, it interacts with
DNA-binding proteins of the T-cell factor/lymphoid-en-
hancer factor family, transforming them from transcrip-
tional repressors into transcriptional activators.
The abnormal activation of Wnt signaling can affect
the expression of numerous genes involved in epithelial
homeostasis, including the oncogenic transcription fac-
tor (TF)-encoding gene MYC. It is one of the genes most
frequently found to be overexpressed in intestinal aden-
omas and carcinomas (and many other tumors as well)
[6,7]. Genes directly targeted by MYC have been identi-
fied in various tumors [8,9], but more recent studies
suggest that this oncogene might be a “universal ampli-
fier” with effects on most of the cell’s actively expressed
genes. This phenomenon might account for the broad
spectrum of effects ascribed to this oncogene in normal
and tumor cells [10,11].
However, while MYC undoubtedly plays a central role in
tumors that overexpress it, the adenomatous phenotype is
likely to be underpinned by transcription networks in
which the expression of numerous TFs is altered. These
networks are characterized by cross-regulation and redun-
dant regulation of component TFs and TF-gene binding
that occurs over a wide range of DNA occupancy levels
[12]. Understanding how the concentration of a given TF
in a neoplastic tissue differs from that in its normal tissue
counterpart is therefore of paramount importance to eluci-
date the tumorigenic process.
Gene expression studies can reveal potentially import-
ant factors in colorectal tumorigenesis by pinpointing
genes with markedly up- or downregulated expression
levels in early precancerous lesions [3,13,14]. For this
reason, we attempted in the present study to compre-
hensively characterize the TF gene expression changes
that occur in colorectal adenomas. Many of the numer-
ous changes we identified involve TF genes that have not
been previously linked to colorectal tumorigenesis. One
of these, DACH1, consistently displayed marked upregu-
lation in the colorectal adenomas we examined, and it
was subjected to further investigation in a series of neo-
plasms representing different types and stages of colo-
rectal tumor progression.
Methods
Microarray data
We analyzed previously collected [13] gene expression
data on 17 pedunculated colorectal adenomas and 17
peritumoral samples of normal mucosa (> 2 cm from
the adenoma). The pathologic features of the tumor
series are summarized in Additional file 1: Table S1.
Human colorectal tissues were prospectively collected
from patients undergoing colonoscopy in the Istituti
Ospitalieri of Cremona, Italy. The approval of the ethics
committee of this institution was obtained, and tissues were
used in accordance with the Declaration of Helsinki. Each
donor provided written informed consent to sample collec-
tion, data analysis, and publication of the findings. Detailed
descriptions of RNA extraction method and the Affymetrix
Exon 1.0 microarray analysis are available in the report of
our original study [13]. Raw transcriptomic data have been
deposited in GEO (accession number GSE21962).
Selection of TF genes
A three-pronged selection procedure (Figure 1) was used
to identify TFs likely to play important but unsuspected
roles in colorectal tumorigenesis. The starting point was
a list of 35,285 genes, i.e., the 23,768 protein-encoding
genes examined in the original study [13] plus 11,517
non-protein-encoding genes.
First (Figure 1, left prong), these genes were screened
against a census of human TFs published in 2009 by
Vaquerizas et al. [15]. This manually curated compil-
ation contains 1987 sequence-specific DNA-binding TF
genes, each with information on its function, genomic
organization, and evolutionary conservation. Most were
identified with the Ensemble Genome Browser [16], but 27
are probable TF genes from other sources, such as Gene
Ontology [GO] or TRANScription FACtor [TRANSFAC]
database [17]. One thousand eight hundred six of the 1987
TF genes in the census were also found in our original data
set. These genes were selected on the basis of gene-level
Brainarray summaries [18] of the Exon 1.0 microarray data,
so exon-level and splicing information were not taken into
account. A detection filter was then applied to select TF
genes likely to be expressed in either normal or adenoma-
tous colorectal tissues. Candidates were thus excluded un-
less their expression values exceeded an arbitrarily defined
cut-off of 5.8 (log2 scale) in ≥ 50% of the samples in one or
both of the tissue groups (adenomas, normal mucosa). The
1218 TF genes selected with this step are listed in
Additional file 2: Table S2. This list was then further re-
duced to include only those TF genes that had exhibited
significantly up- or downregulated expression in the aden-
omas vs. normal mucosa (TF genes in bold face in
Additional file 2: Table S2). For this final selection, a p value
threshold of < 0.01 in a paired two-tailed t test was chosen.
Unadjusted p values were used for the ranking, which is
not influenced by multiple testing correction [19].
The second and third prongs of the selection proced-
ure (Figure 1, middle and right-hand columns) began
with analysis of TF genes in the original data set with
commercially available MetaCore™ software (version
6.14, build 61508) from GeneGo, Inc. In MetaCore, each
gene is assigned to a network of related genes (e.g., a TF
gene is included in a network of genes that it likely
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regulates). Network size varies widely: some contain less
than 10 genes, others (like that of the transcription fac-
tor SP1), well over 2000. The MetaCore TF analysis used
the hypergeometric test to select TF genes regulating
networks enriched in genes that had displayed signifi-
cant differential expression in our adenomas, as com-
pared with normal mucosa. The results are expressed in
terms of a z-score, which reflects the deviation stretch
from the mean of a normally distributed population, and
a p value, which is inversely correlated with the signifi-
cance of the TF network (Additional file 3: Table S3).
We set a relaxed significance threshold (a t-test p value
of 0.2 and an absolute logarithmic fold change of 0.2) to
select TF networks with enough significant elements to
allow efficient calculation of enrichment. The signifi-
cance of a given TF gene network in the context of the
selected genes, measured by hypergeometric test, is de-
scribed by its p value and additionally by the z-score of
network enrichment. The 793 TF genes whose networks
were enriched in genes displaying significant differential
expression in adenomas (Figure 1) are listed in Add-
itional file 4: Table S4, where those with z-scores > 2 are
reported in bold-face type.
MetaCore is based on a curated database of human
protein-protein and protein-DNA interactions, transcrip-
tion factors, signaling and metabolic pathways, diseases and
toxicity, and the effects of bioactive molecules. It is con-
structed and edited manually by GeneGo scientists on the
basis of data from full-text articles published in relevant
journals (https://portal.genego.com). The size of a gene
network therefore depends on the data (and therefore the
number of publications) available on a given gene. In
GeneGo, TF significance (measured by the parameters
described above) is related to network size. Therefore,
genes that have been researched more intensively and are
therefore well-represented in published reports might be
Figure 1 Three-pronged procedure used to select 261 transcription factor (TF) genes with probable but relatively unexplored roles in
colorectal tumorigenesis. The initial data set included 35,285 genes (including 23,768 annotated protein-encoding genes) represented on the
Affymetrix Exon 1.0 microarray used to analyze 17 colorectal adenomas and corresponding specimens of normal mucosa. Left prong: Selection of
315 genes that encode TFs, are expressed in normal and/or adenomatous colorectal mucosa, and display significantly up- or downregulated
transcription in adenomas. Middle and right prongs: MetaCore TF analysis identified 793 TF genes whose interaction networks were enriched for
genes that were significantly up- or downregulated in adenomas. This list was then filtered to identify those with z scores of ≥2 (n = 257) and
those with NormPDIs of >0 (n = 495) (see Methods section for details).
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reported as more significant than those that have been less
thoroughly investigated. In other words, higher connectivity
might be partly rooted in investigative biases.
The third prong of our selection procedure (Figure 1)
was designed to correct for such biases by identifying
TFs that are under-represented in scientific publications
dealing with colorectal tumors. For each TF gene identi-
fied by the Metacore analysis, we manually reviewed the
GeneCard (www.genecards.org) links to research articles
dealing with the gene indexed in PubMed (as well as Novo-
seek, HGNC, Entrez Gene, UniProB, PharmaGKB and/or
GAD) and recorded the number of articles that also dealt
with colorectal tumors (actual publications). Correlation
between the number of actual publications and the z-score
of each TF gene was assessed with a scatter plot, and a
trend line was drawn to identify the expected number of
publications for each TF (Additional file 5: Figure S1). The
trend line was obtained by multiplying the z-score for each
TF by the slope value (142 in this case, with the fixed inter-
cept = 0). The correlation was fairly strong (=0.4) for such
heterogeneous data, so the linear approximation appeared
to be justified. By subtracting the actual number from the
expected number of publications calculated for each TF, the
difference in publications (DP) was obtained. The normal-
ized DP (NormDP) was then calculated [i.e., NormDP =
(actual - expected publication number)/expected publica-
tion number], which correlates with the distance to the
trend line. Higher NormDPs reflect larger discrepancies
between the expected and actual numbers of publications
and are therefore associated with TFs whose possible
links to colorectal tumorigenesis have been relatively
“under-researched.” The TF genes with a NormDP > 0
were therefore termed "under-researched" (the 495 TF
genes in red colour in Additional file 4: Table S4).
Their importance and number of connections in the
Metacore database may be underestimated owing to
their limited presence in the literature.
The TF gene sets generated by the three selection pro-
cedures were compared and their intersections repre-
sented in a Venn diagram (see Results and Discussion
sections). Hierarchical clustering analysis of the micro-
array data was carried out using heatmap.2 function
from the gplots library (CRAN repository at http://cran.
rproject.org/web/packages/gplots/index.html) with Pearson
correlation as a distance function and Ward agglomeration
method for clustering.
The TF gene expression perturbations found in our
adenoma series were also compared with those reported
in advanced colorectal tumors. For this purpose, we ap-
plied the same TF gene selection procedure to the Exon
1.0 microarray-based, gene expression data reported by
Maglietta et al. [14] (raw data available in Array Express
E-MTAB-829) relative to 13 colorectal carcinomas and
paired samples of normal mucosa.
Immunohistochemistry
Immunostaining was used to assess DACH1 protein ex-
pression patterns in 20 archival, formalin-fixed, paraffin-
embedded colorectal adenomas, 80 sporadic colorectal
cancers, and the normal mucosa adjacent to these latter
lesions. The cancers represented different stages and
histologic grades (Additional file 6: Table S5). Forty were
classified as mismatch repair (MMR)-proficient and 40
as MMR-deficient based on immunostaining for the pro-
tein encoded by the MMR gene MLH1, whose lack of
expression in sporadic cancer is caused by CpG island
hypermethylation at its promoter [20]. MLH1 protein
expression in a cancer tissue is usually uniformly strong
(indicating MMR proficiency) or completely absent
(MMR deficiency) [20].
In brief, 4-μm sections of each cancer were mounted
on glass slides coated with organosilane (DakoCytoma-
tion), deparaffinized, and rehydrated. Antigen retrieval
was accomplished by heating the sections in a pressure
cooker at 120°C for 2 min in 10 mM citrate-buffered so-
lution (pH 6.0). DAKO peroxidase-blocking reagent and
goat serum were used sequentially to suppress nonspe-
cific staining due to endogenous peroxidase activity and
nonspecific antibody binding, respectively. Sections were
then incubated overnight at 4°C with the primary anti-
body (mouse monoclonal anti-MLH1 antibody [BD,
no. 551091, 1:200 dilution] or rabbit polyclonal anti-
DACH1 antibody [Sigma, no. HPA012672, 1:400 dilu-
tion]). The sections were washed, and appropriate
secondary antibodies conjugated to peroxidase-labeled
polymer (DAKO EnVision + kit) were applied for
30 min at RT. Finally, the sections were incubated with
3,3’diaminobenzidine chromogen solution (DAKO) to
develop the peroxidase activity and then counter-
stained with hematoxylin.
DACH1 immunostaining patterns proved to be com-
plex and were evaluated as follows. The extension of
staining in each cancer specimen (i.e., the percentage of
tumor cells displaying any degree of staining) was rated
as absent (no stained cells); limited (≤ 35% cells); moder-
ate (36%–69%); or extensive (70%–100%). As for immu-
nostaining intensity, scores were first assigned to various
areas of the cancer (1 = weak; 2 =moderate; 3 = strong).
The highest score assigned anywhere in the cancer spe-
cimen was then added to the score that was most repre-
sentative of the specimen. The sum was an intensity
score ranging from 2 to 6. The Fisher exact test was
used to examine the significance of associations between
extension or intensity DACH1 staining score and various
characteristics of the cancers (MMR status, TNM stage,
and histologic grade).
The specificity of the DACH1 antibody we used was
verified in immunostaining experiments performed as
described above on sections of formalin-fixed, paraffin-
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embedded pellets made from colon cancer cell lines with
different DACH1 gene expression levels.
Evaluation of DACH1 promoter methylation status in
colorectal cancers
Using the QIAamp DNA FFPE Tissue kit (Qiagen, no.
56404), we extracted DNA from 18 of the 80 cancers de-
scribed above. DACH1 expression in these cancers was
marked and ubiquitous in 6, patchy in 6, and completely
lost in 6 (see examples in the Results section), and each
of these 3 groups included 3 tumors that were MMR-
proficient and 3 that were MMR-deficient. Sodium bisulfite
conversion of genomic DNA was performed as previously
described [21], and the resulting DNA was subjected to
combined bisulfite restriction analysis (COBRA) to deter-
mine the methylation status of two CpG islands located
respectively upstream the transcription start site (CpG I)
and in the first intron (CpG II) of the DACH1 gene.
Amplifications were carried out with FastStart Taq DNA
Polymerase (Roche, Basel, Switzerland) with the following
primers: CpG I: 5’-GTAGTAGTAGAAGAGAAGTAGAT
GA-3’ (sense) and 5’- ACCCAAATTATCCAACCAAAA
ACTC-3’ (antisense); CpG II: 5’-GGGTGAGGGTTTIGT
TGGGA-3’ (sense) and 5’-CCCTCCCCTCIACTAACT
TC-3’ (antisense). The amplified products were digested
with the TaqαI restriction enzyme (New England Biolabs,
Beverly, MA, USA) and subjected to 2% agarose gel elec-
trophoresis and ethidium bromide staining.
Results
To isolate bona fide TFs from our original set of 35,285
genes, we screened it against the census of 1987 human
TFs compiled by Vaquerizas et al. [15]. As shown in
Figure 1 (left-hand prong), 1806 of the 1987 TF genes
were identified among those in our original set, but only
1218 of these were significantly expressed in either nor-
mal colorectal mucosa or in colorectal adenomas or in
both (see Methods). The expression levels of these 1218
TF genes in the normal and neoplastic tissue groups are
illustrated in a hierarchical clustering analysis of the 34
tissue samples (Additional file 7: Figure S2). As shown in
Figure 1 (and detailed in Additional file 2: Table S2), 315
of the 1218 TF genes were found to be significantly
over- or under-expressed in adenomas relative to normal
mucosa (t test: p < 0.01).
Parallel MetaCore analysis of the original gene set
identified 793 TF genes whose interaction networks were
enriched for genes displaying significant differential ex-
pression in adenomas, as compared with normal mucosa
samples (Additional file 4: Table S4). This list, which was
generated with the relatively relaxed criteria described in
the Methods section, was then filtered (Figure 1, right-
hand prong) to select the TF genes most likely to be in-
volved in adenomatous transformation of the colorectal
epithelium. The result was a list of 257 TF genes with
z-scores ≥ 2 in the hypergeometric enrichment test,
reflecting gene expression changes in adenomas amount-
ing to at least 2 standard deviations from the mean ex-
pression change.
In parallel, the MetaCore list of 793 TF genes was
filtered to identify those whose possible role in colorectal
tumorigenesis has been relatively under-researched
(Figure 1, middle prong), as defined by the NormDP
(see Methods). This analysis pinpointed 495 of the 793
TF genes with fewer than expected publications on
their involvement in colorectal tumorigenesis (i.e.,
NormDPs of >0; Additional file 4: Table S4).
Figure 2 shows the intersections of the three TF gene
sets obtained with the procedures described above. Two
hundred sixty one were identified with at least two selection
procedures (Additional file 8: Table S8). Hierarchical clus-
tering analysis of the 34 tissue samples based on the expres-
sion levels of these TF genes showed clear separation of the
adenomas and normal mucosa samples (Figure 3). The
sub-clusters of adenomas and normal samples seen in
Figure 3 showed no correlation with the known clinical and
pathologic features of the tissues (Additional file 1: Table
S1), which is not particularly surprising given the relatively
small number of samples analyzed.
We then used two different approaches to identify TF
genes listed in Additional file 8: Table S8 that might be
candidates for subsequent validation studies as drivers of
colorectal transformation. First, using manual inspection
Figure 2 Venn diagram showing intersection of TF gene sets
selected in Figure 1. One thousand sixty seven TF genes were
identified in at least one of the three selection procedures described
in Figure 1. Two hundred sixty-one TF genes were identified in
two of the selection procedures and 55 were selected in all three
procedures.
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of the list, we selected the TF genes with the following
characteristics: marked upregulation in adenomas (i.e.,
top upregulated genes in Additional file 8: Table S8) and
no actual publications on the possible roles in colorectal
tumorigenesis (regardless of whether research had been
published on their involvement in other types of tumori-
genesis). Upregulated TF genes were chosen since they
were also more likely to represent potential biomarkers
of adenomatous transformation.
One of the genes that met these criteria was DACH1.
Microarray data from a previous study by our group [3]
had indicated that its expression is also upregulated in
most colorectal cancers, although significantly reduced
mRNA levels were observed in some of the cancers
tested, all of which were MMR-deficient (Figure 4). This
observation prompted us to conduct immunohistochem-
istry experiments to investigate DACH1 protein expres-
sion in colorectal adenomas and in colorectal cancers of
different stages, histologic grades, and MMR status (40
MMR + and 40 MMR-, Additional file 6: Table S5).
The DACH1 antibody used for these studies displayed
excellent specificity, as shown by Additional file 9:
Figure S3. Immunostaining of normal mucosa revealed
high nuclear expression of DACH1, which was confined
mainly to the proliferating cells in the lower half of colo-
rectal crypts (Figure 5A). Nuclear expression was also
invariably strong in the adenomas we tested, but in this
case it was almost ubiquitous (Figure 5B and C). As for
the cancers, three different staining patterns emerged:
marked and ubiquitous DACH1 expression resembling
Figure 3 Hierarchical clustering analysis of colorectal tissue samples based on the TF genes found in two of the three sets shown
in Figure 1. (Pearson correlation, Ward distance). The 34 tissue samples represented on the x-axis include 17 normal mucosal samples and 17
adenomas. Each transcript probe set plotted on the y-axis is color-coded to reflect expression levels of the TF genes relative to their median
expression levels across the entire tissue-sample set (red: high; green: low). Two hundred fifty-two of the 261 TF genes listed in Additional file 8:
Table S8 are reported here: the other 9 (i.e., the last 9 in Additional file 8: Table S8) were not among the 35,285 genes represented on the
Affymetrix Exon 1.0 microarray platform, but they were considered in networks generated with the MetaCore TF analysis.
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that seen in adenomas (Figure 5D); complete loss of ex-
pression throughout the lesion (Figure 5E); and patches
of variable-intensity staining interspersed with areas of
absent expression (Figure 5F). The latter two patterns
were significantly more frequent in MMR- cancers (30/
40 vs. 11/40 of those that were MMR+). Fisher’s exact
tests showed that DACH1 expression in MMR- cancers
was significantly more likely to be partially/completely
lost (staining extension: <70% of cells; p = 0.00016) or
relatively weak (intensity scores of <5) (p = 0.054) than
that observed in MMR+ cancers. DACH1 staining inten-
sity scores were also significantly lower in poorly differ-
entiated (G3) cancers (p = 0.019 vs. G2 cancers), which
were (as expected [20]) significantly associated with
MMR deficiency (P = 0.0019). DACH1 staining patterns
did not appear to be related to TNM stages, although
this finding needs to be confirmed in larger groups of
MMR+ and MMR- cancers.
Because our MMR- cancers showed loss of gene
expression due to epigenetic silencing of the MMR gene
MLH1, we wondered whether their diminished DACH1 ex-
pression might be caused by methylation at the DACH1
promoter. The COBRA experiments we performed failed
to confirm this hypothesis. The CpG island located in
the DACH1 promoter (CpG I in Figure 6A, primers in
Methods) was not found to be methylated in any of the 18
cancers we tested (samples from each DACH1 staining pat-
tern group are shown in Figure 6B). Hypermethylation at
this site may occur in vitro, however, as shown for the
colon cancer cell lines HCT116 and CO115 (Figure 6B).
Similar results were obtained with the COBRA analysis of a
different CpG island located in the first intron of the
DACH1 gene (CpG II in Figure 6A).
The second approach we used involved the identifica-
tion of genes that might represent important hubs in the
transcriptional network of adenomas (as opposed to the
one operating in the normal mucosa). To this end, we
uploaded the 55 significant TF genes identified by all
three selection procedures (Figure 2) into the MetaCore
database and ran a comparative analysis of their networks.
The most promising network included the following five
target genes: TGF-beta 1 (TGFB1),TERT, Survivin (BIRC5),
c-Myb (MYB), and GCR-alpha (NR3C1) (see Figure 7, and
Additional file 10: Figure S4 and Additional file 11: Figure
Figure 4 DACH1mRNA expression in normal colorectal mucosa, colorectal adenomas, and mismatch repair (MMR)-deficient and -proficient
colorectal cancers. Scatter plot of normalized log2 expression intensity values for DACH1 (Affymetrix U133 Plus 2.0 array analysis) in the 4 tissue groups
analyzed in our previous study [3]. Means and standard errors are represented by horizontal lines and t-bars, respectively.
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S5). This network was characterized by a p value of
3.43e-64 and 75 target genes, including 27 “seeds”, i.e.,
TF genes. These findings will be discussed in the next
section.
Finally, we compared the perturbations of TF gene ex-
pression documented in our colorectal adenomas with
those reported by Maglietta et al. [14] in 13 colorectal
carcinomas and paired normal mucosa samples. These
latter tissue pairs were a subset of the 17 analyzed by
Maglietta et al. They were selected because they had all
been processed in the same laboratory [14]. As shown in
Additional file 12: Figure S6), a substantial proportion of
TF genes whose expression was dysregulated in the car-
cinomas were also dysregulated in our adenomas (46%
using the t test based-approach of the left prong of our
selection procedure, 57% using the MetaCore-based ap-
proach of the right prong [Figure 1]). The TF genes
identified in colorectal carcinomas with these two ap-
proaches are reported in Additional file 13: Table S6 and
Additional file 14: Table S7).
Figure 5 Immunohistochemical staining for DACH1 protein in normal and neoplastic colon. (A) In normal mucosa, DACH1 expression is
present in the nuclei of proliferating cells in the lower portion of the epithelial crypts (black arrowhead) and completely absent in the
differentiated cells in the upper crypts (red arrowhead). (B) High-level DACH1 expression is seen in rapidly proliferating cells of adenomatous
glands taking over normal crypts. Abundant expression is also seen in most cells of a colorectal adenoma (C) and a colorectal carcinoma (D).
In another colorectal cancer (E), DACH1 expression is absent in neoplastic glands, although proliferating cells in the normal mucosa and in the
tumoral stroma are positive. (F) A third colorectal cancer with patchy staining for DACH1.
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Discussion
The aim of this study was to identify TF genes with
probable roles in the early stages of colorectal tumori-
genesis, especially those whose roles in this setting have
been less extensively investigated. The list we compiled
contained 261 TF genes, including one, DACH1, which
appeared particularly interesting. It was invariably over-
expressed in the preinvasive stage of colorectal tumori-
genesis (i.e., adenomas) and frequently upregulated in
colorectal cancers as well. However, it was found to be
silenced in certain colorectal cancers, especially those
that were MMR-.
To our knowledge, this is the first attempt to compre-
hensively characterize the TF gene transcriptome of hu-
man colorectal adenomatous polyps, although several
studies have been published on the overall transcrip-
tional profile of colorectal tumors (GEO database [22]
and our previous reports [3,13,23]). Vaquerizas et al.
studied TF gene expression changes in 32 healthy hu-
man tissue types, but, surprisingly, the colorectum was
not included.
The focus of our study was the adenomatous colorec-
tal polyp (as compared with corresponding samples of
normal colorectal mucosa), and genes were considered
to be expressed in these tissues only if they had expres-
sion levels of ≥5.8 (log scale). This cutoff, which was
chosen on the basis of our previous observations and
the recommendations of the microarray manufacturer
(Affymetrix), is less stringent than the one used by
Vaquerizas et al. [15]. We deliberately chose a more re-
laxed cutoff to maximize our chances of identifying all
TFs involved in colorectal carcinogenesis, even those
with low-level expression. This is important because TF
mRNA and TF proteins are less stable than those of
other classes of genes [24], and TF protein levels span
over four orders of magnitude [12]. The number of TF
genes that met our criterion for expression in normal or
adenomatous colorectal tissue (or both)—1218—was
thus markedly higher than those reported by Vaquerizas
et al. in normal tissues of other organ systems, which
ranged from 150 to 300 [15]. The U133 Plus 2.0 array
used by these investigators is also less sensitive than the
Figure 6 Methylation analysis of the CpG island in the DACH1 promoter. (A): Schematic depiction of the CpG islands located respectively 5’
upstream from the DACH1 transcription start site (CpG I) and in the first intron of the DACH1 gene (CpG II). (B): Examples of CpG I COBRA analysis
in colorectal cancers with intense (red), patchy (green), or no (blue) DACH1 protein immunostaining and in 4 colon cancer cell lines characterized
by low (HT29 and Caco2) or very low (HCT116 and CO115) DACH1 expression (based on microarray-documented DACH1 mRNA expression levels - see also
Additional file 9). Asterisks indicate TaqαI-digested DNA fragments representing methylated alleles; slower-migrating fragments correspond to undigested,
unmethylated DNA. MW, molecular weight; bp, base pair.
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Affymetrix exon array platform we used [13]. In spite of
these differences, however, in both studies, TF genes rep-
resented ~7% of all genes classified as “expressed” genes
in most of the tissues examined.
The three-pronged selection procedure we used to
identify TF genes involved in colorectal tumorigenesis
generated a final list of 261 candidates (Additional file 8:
Table S8). At the time of our analysis, only 15% of these
genes had been implicated (putatively or otherwise) in
colorectal tumorigenesis in more than 10 publications,
including a few like MYC and TP53, whose links to this
process are well-established. And for 102 (39%) of the
candidate genes, our literature search revealed no data
at all on their possible roles in colorectal tumors.
To extract meaningful biological information from this
list, we initially focused on the TF genes displaying the
most markedly upregulated expression in colorectal ad-
enomas together with the lowest publication scores. One
of the top genes in this subgroup was DACH1, a human
homolog of the Drosophila melanogaster TF gene dachs-
hund, which is essential for proper proliferation and
differentiation of retinal and leg precursor cell popula-
tions in these flies [25-27]. DACH1 appears to regulate
the transcription of several human genes involved in
proliferation (e.g., CDKN1B, CCND1, JUN, and TGFb)
[28-32]. Furthermore, our immunohistochemistry stud-
ies revealed abundant DACH1 expression in the nuclei
of epithelial cells in the lower half of normal colorectal
crypts (Figure 5A), where proliferation predominates over
differentiation. Therefore, the staining pattern strongly as-
sociates DACH1 expression with cell proliferation and/or
commitment to cell differentiation. It has also recently
found to be highly expressed in cycling intestinal stem cells
from mice [33].
In line with these findings, the expression of DACH1
mRNA and protein was significantly increased in tumor
lesions (Figures 4 and 5C/D), which are extensively pop-
ulated by proliferating cells. However, it does not appear
to be indispensable for cancer-cell proliferation and can-
cer progression since some of the colorectal cancers we
examined were characterized by complete or partial loss
of DACH1 protein expression (Figure 5E and F). These
Figure 7 Organic (hub-centric) layout of the most significant network identified by MetaCore. The network includes 27 of the 55 TF genes
found in all three sets depicted in Figure 2.
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losses showed no correlation with the TNM stages of
the cancers, but they were significantly more frequent in
tumors that were poorly differentiated and/or MMR
deficient.
The mismatch repair defect was the result of epigenetic
silencing of the MLH1 gene, and a similar phenomenon
might have been responsible for the loss of DACH1 expres-
sion in some cancers. However, COBRA revealed no evi-
dence of cytosine hypermethylation at the CpG islands
investigated (Figure 6A) in any of the colorectal cancers we
examined (although analysis of colon cancer cell lines indi-
cated that this phenomenon can occur in vitro) (Figure 6B).
The loss of DACH1 in certain cancers might stem from
cytosine hypermethylation at other possible regulatory re-
gions of the DACH1 locus or from other types of epigenetic
changes at this site. Additional work is needed to explore
these possibilities. In any case, histone modifications are
likely to play some role in the silencing of this gene.
DACH1 is one of the developmental TF genes whose chro-
matin in mouse embryonic stem cells is bivalent, i.e., it
harbors permissive as well as repressive histone marks
(Figure 2 in [34]). This epigenetic conformation, which fa-
cilitates the gene’s ability to switch rapidly between tran-
scriptionally active and inactive states, might account for
the staining patterns shown in Figure 5.
Altered DACH1 expression has already been reported
in other human tumors. In a study of lung cancers based
on whole-genome sequencing, DACH1 emerged as a
biologically significant target of mutation (loss-of-func-
tion alterations in particular) [35], and its homozygous
deletion has been reported in some glioblastoma multi-
formes [36]. More recently, DACH1 has been reported to
inhibit the growth of lung adenocarcinoma cells through its
binding to TP53 [37]. DACH1’s putative tumor suppressive
function has also been documented in studies of breast,
prostate, and uterine cancers (reviewed in [38]), where its
expression was found to be frequently downregulated. In
contrast, upregulated expression has been reported in
advanced ovarian cancers [39] and in CD15+ myeloid pro-
genitor cells harboring the t(9;11) translocation [40], and
there is some evidence that it exerts oncogenic effects in
t(9;11) acute myeloid leukemia [41].
In light of these findings, the transcription-regulating
roles of DACH1 in somatic tissues—and their implica-
tions for tumorigenesis in a given tissue— might be ex-
pected to vary widely. The anti-DACH1 antibody used in
our study is highly reliable for exploring this question,
but it has been commercially available only recently.
Immunostaining patterns in extracolonic tissues and tu-
mors obtained with older antibodies might therefore
need to be re-examined.
A second approach used in the analysis of the TF
genes listed in Additional file 8: Table S8 involved the
identification of hub genes in networks that could be
built with the selected TF genes. Like many other pro-
teins, TFs interact with the products of other genes.
Interaction networks are very useful to better under-
stand the functional significance of gene expression
changes. Each TF influences the expression of several
genes, producing changes in the levels of mRNA and, in
many cases, also in the levels of the corresponding pro-
teins. Thus, it is important to know the expression level
of the TF gene itself, but also that of the other genes in
its network(s).
For this reason, we used GeneGo (portal.genego.com)
to build networks using the 55 TF genes identified by all
three of our selection procedures. The most significant
network included 27 of the 55 TF genes. Each of the
five hub genes identified within this network (TGFB1,
BIRC5, NR3C1, MYB, and TERT) (Figure 7) is known to
play roles in at least one fundamental cellular process in-
volved in tumorigenesis [42-47]. Figure 8 shows how the
expression of these hub genes changes as normal colo-
rectal mucosa undergoes adenomatous transformation.
The downregulated TFGB1 transcription we observed in
colorectal adenomas (Figure 8) is consistent with previ-
ous reports, which described upregulation of this gene
only in advanced colorectal tumors (severely dysplastic
adenomas and cancers) [48-50]. These findings suggest
that the proapoptotic function of TGFB1 [51], which is
important for maintenance of homeostasis in the normal
colorectal epithelium, might decline in the early phases
of colorectal tumor growth. Indeed, sulindac treatment
has been shown to upregulate apoptosis in certain areas
of colorectal adenomas, and these same areas also displayed
increased TGFB1 expression [52]. TGFB1’s growth inhib-
ition is believed to be replaced by tumor-promoting func-
tions, i.e., immunosuppression and angiogenesis, in more
advanced tumors, where its expression is in fact increased
[51]. Impaired apoptosis, an essential feature of early aden-
omatous growth, might also be related to the increased
expression of BIRC5 we documented in our adenomas
(Figure 8). BIRC5 is a well-known member of the in-
hibitor of apoptosis gene family [45], and its overex-
pression in precancerous colorectal lesions has been
well-documented [53-56].
It is more difficult to predict the functional impact on
colorectal tumorigenesis of the striking downregulated
expression of the glucocorticoid receptor gene NR3C1
in all the adenomas we examined (Figure 8). The mecha-
nisms underlying this nuclear receptor’s control of
transcription in the intestinal epithelium (and other tis-
sues or cells) are still unknown [57]. Its decreased ex-
pression in our adenomas might be related to epigenetic
modifications involving its promoter region, which
could eventually lead to cytosine hypermethylation as
these lesions progress [58]. Upregulated MYB expres-
sion (Figure 8) has already been reported in human
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and mouse colorectal tumors, including adenomas
[59]. In APC (Min/+) mice that are also haploinsuffi-
cient for Myb, adenoma formation is delayed, and co-
operation between Myb and Wnt signaling appears to
play a crucial role in this process [60].
As for TERT, the fifth hub in this network, its expres-
sion in our adenomas was not significantly different
from that in normal mucosa (Figure 8). TERT is normally
expressed in progenitor cells, and its overexpression has
been implicated in the transformation of colorectal epithelia
and many other types of tumorigenesis as well. Its expres-
sion in colorectal adenomas has not been investigated in
large studies, but it appears to undergo a gradual increase
during progression from adenomas to carcinomas [61,62].
Our adenomas were probably not advanced enough to dis-
play significantly upregulated TERT expression (all were
larger than 10 mm, but most were characterized by low-
level dysplasia). Nonetheless, TERT’s putative role as a
major player in colorectal cellular transformation emerged
from our MetaCore TF analysis, owing in all probability to
significant expression changes involving other molecules
that interact with TERT in the same network.
In a previous report, we provided a thorough description
of the sequential dysregulation of biological pathways that
occurs along the adenoma-to-carcinoma sequence, based
on analysis of our transcriptomic data [14]. In the present
study, we focused on precancerous colorectal lesions and
compared our findings with those obtained in colorectal
carcinomas using the same approach depicted in Figure 1.
Roughly half the TF gene expression perturbations found in
carcinomas were already evident in adenomas (Additional
file 12: Figure S6; genes listed in Additional file 13: Table
S6 and Additional file 14: Table S7), suggesting that the
tumorigenic transcriptional program is already well under-
way during the preinvasive stage. However, a similarly large
proportion of TF genes were dysregulated only in carcin-
omas, which indicates that this program undergoes an im-
portant change across the adenoma-to-cancer transition.
Extensive validation studies will be necessary to shed light
on the biological and clinical implications of the similarities
Figure 8 Transcript levels in colorectal adenomas and normal mucosa for the five target (hub) genes in the TF network shown
in Figure 7. Scatter plots of normalized log2 expression intensity values (y-axis) obtained by Affymetrix Exon 1.0 array analysis of 17 colorectal
adenomas and their corresponding samples of normal mucosa. Means and standard errors are represented by horizontal lines and t-bars,
respectively. Mean fold changes in adenomas (vs. normal mucosa) are shown for each gene.
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and differences of the transcriptional program between
these two stages of transformation.
Conclusions
This study provides novel information on the TF gene
transcript levels associated with adenomatous transform-
ation of the colorectal epithelium and identifies 261 TF
genes that appear to play roles in colorectal tumorigen-
esis. We pinpointed the TF genes whose expression is
significantly altered in colorectal adenomas and charac-
terized the extent and direction of these changes. Inte-
grating these findings with those observed in the entire
transcriptome allowed us to identify a few hub genes,
which may play crucial roles in the formation and pro-
gression of adenomas. Finally, we provide useful infor-
mation on numerous TF genes whose roles in colorectal
tumorigenesis have been relatively unexplored, such as
DACH1, a development gene whose protein expression
patterns in colorectal tissues raises interesting questions
about its involvement in tumor growth. This study rep-
resents a very early step toward a better understanding
the highly complex transcription network of a given tis-
sue and tumor. The function of any TF does not depend
solely on its expression level but on many other aspects,
such as DNA occupancy levels and the tissue-specific
availability of factors it interacts with [12,57]. Our find-
ings must be complemented with studies designed to
address these aspects of the transcriptional network in
colorectal tissues.
Additional files
Additional file 1: Table S1. Characteristics of the 17 patients with
pedunculated adenomas included in the study.
Additional file 2: Table S2. Differential expression of 1218 TF genes in
colorectal adenomas and corresponding normal mucosa samples. Genes
are listed in order of ascending p value; bold-face type: 315 genes with a
p value <0.01.
Additional file 3: Table S3. Legend of numeric attributes in the
MetaCore TF analysis.
Additional file 4: Table S4. The 793 TF genes whose networks were
enriched in genes displaying significant differential expression in
adenomas (Figure 1, MetaCore analysis). Genes are listed in order of
descending z-score. Bold-face type: genes with a z-scores > 2; red:
"under-researched" genes (NormDP > 0).
Additional file 5: Figure S1. Actual and expected numbers of
colorectal tumorigenesis-related publications dealing with each TF gene.
Relationship between z-score (x-axis) and actual number of publications
(y-axis) for each TF gene. The trend line has an intercept = 0 and a slope
alpha = 142. The alpha value can be used to predict the expected number
of publications. This allowed us to distinguish between TFs that have
been "under-researched” (below the trend line) and "over-researched“
(above the trend line) in the field of colorectal tumorigenesis.
Additional file 6: Table S5. Characteristics of the 80 colon cancer
patients tested for DACH1 expression.
Additional file 7: Figure S2. Hierarchical clustering analysis of
colorectal tissue samples based on expression levels of 1218 TF genes.
(Pearson correlation, Ward distance). The 34 tissue samples represented
on the x-axis include 17 normal mucosal samples (normal) and 17
adenomas (adenoma). Each transcript probe set plotted on the y-axis is
color-coded to reflect expression levels of the 1218 TF genes relative to
their median expression levels across the entire tissue-sample set (red:
high; green: low).
Additional file 8: Table S8. Scores of 261 TF genes that passed at least
2 of the 3 selection thresholds shown in Figure 1. Genes are listed in the
order of ascending p values.
Additional file 9: Figure S3. DACH1 immunohistochemical staining of
sections from formalin-fixed, paraffin-embedded pellets of 6 colon cancer
cell lines. Affymetrix U133Plus2.0 raw mRNA DACH1 expression values are
reported for each cell line. These gene expression levels were consistent
with the complete absence of DACH1 protein in CO115 cells (A) and its
extremely weak expression in HCT116 cells (B). Strongly stained nuclei
were rare in the population of Caco2 cells (C) but much more common
in LS180 cells (D). Most of the SW620 cell nuclei were positive for DACH1
expression, which is consistent with the high DACH1 mRNA expression
value for these cells (E). Interestingly, DACH1 expression was absent in
SW480 cells (F), which were established from a primary colon cancer
whose lymph node metastasis was used to establish the SW620 cell line.
Additional file 10: Figure S4. Legend of the symbolic attributes of the
gene networks shown in Figure 7 and Additional file 11: Figure S5.
Additional file 11: Figure S5. The most significant network included
27 of the 55 TF genes found in all three sets depicted in Figure 2. In this
panel, the subcellular localization layout of MetaCore is shown.
Additional file 12: Figure S6. Venn diagrams showing intersection of
TF gene sets identified in our analyses of colorectal adenomas and
carcinomas (each compared with matched samples of normal mucosa).
Top diagram: The number of TF genes was identified with the t test-
based procedure shown in Figure 1 (left prong). Bottom diagram: The
number of TF genes was identified with the MetaCore-based procedure
shown in Figure 1 (right prong). Note that the number of TF genes
identified with the latter approach in adenomas and carcinomas refer to
version 6.16, build 63671 of MetaCore™ software.
Additional file 13: Table S6. Differential expression of 1038 TF genes
in colorectal carcinomas vs. corresponding samples of normal mucosa.
Genes are listed in order of ascending p values. Bold-face type: 232 genes
with a p value <0.01. The 107 TF genes listed in red were also dysregu-
lated in adenomas (see Venn diagram in Additional file 11: Figure S5).
Additional file 14: Table S7. The 633 TF genes whose networks were
enriched in genes displaying significant differential expression in
carcinomas (MetaCore analysis). Genes are listed in order of descending
z-scores. The 255 genes listed in bold-face type had z-scores of > 2.
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